vTv Therapeutics Inc.
NASDAQ:VTVTBiotechnology
+$0.50 today
- Market cap
- $64.17M
- Beta
- 0.27
- P/E (TTM)
- 128.7
- EPS (TTM)
- $0.27
Volume 0.02M
Average 0.05M
VTVT Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
vTv Therapeutics Inc.NASDAQ: VTVT
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 215.8% from a year ago
Cash & equivalents stood at $98.09M at the end of Q1 FY2026, up 215.8% from a year earlier and up 10.3% from the prior quarter. Over 3 fiscal years it compounded at +94.3% a year.
Context
- Cash & equivalents amounted to 99.3% of total assets at the end of Q1 FY2026, up 2.3 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +215.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 88.93M USD
- Year-over-year change
- +142.0%
- 4-year CAGR
- +60.5%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 88.93M | +142.0% |
| FY2024 | 2024-12-31 | 36.75M | +289.0% |
| FY2023 | 2023-12-31 | 9.45M | -22.1% |
| FY2022 | 2022-12-31 | 12.13M | -9.6% |
| FY2021 | 2021-12-31 | 13.42M | — |
Cash & Equivalents vs competitors
How VTVT compares with its peers on the latest reported figures
- VTVT's Mar 2026 cash & equivalents of $98.09M is the 3rd highest of the 9 companies compared; the peer median is $19.26M.
- Its year-over-year change of +215.8% is the 2nd highest of 9, against a peer median of +96.7%.
- Cash & equivalents amounts to 99.3% of total assets for VTVT, versus a peer median of 89.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
OSTXOS Therapies Incorporated | Mar 2026 | $917.55M | +30783.5% | +1063.1% | 12570.5% |
| Mar 2026 | $255.84M | +180.1% | -23.6% | 71.7% | |
| Mar 2026 | $98.09M | +215.8% | +94.3% | 99.3% | |
| Mar 2026 | $54.08M | +111.1% | +25.9% | 96.3% | |
| Jun 2026 | $21.99M | -71.7% | -23.5% | 91.0% | |
| Mar 2026 | $16.54M | +82.3% | +41.8% | 88.3% | |
| Mar 2026 | $9.53M | +194.5% | -12.0% | 91.8% | |
| Mar 2026 | $7.75M | +2.5% | -22.5% | 35.4% | |
| Mar 2026 | $6.71M | +21.0% | -27.0% | 56.4% | |
| Peer median (excluding VTVT) | $19.26M | +96.7% | -17.3% | 89.6% | |
Competitors are the stored peer set for VTVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 13.42M | 12.13M | 9.45M | 36.75M | 88.93M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 57K | 12.42M | 102K | 62K | 0 |
| Inventory | 100K | 0 | 0 | 0 | 0 |
| Other Current Assets | 35K | 15K | 65K | 113K | 218K |
| Total Current Assets | 15.62M | 27.09M | 10.66M | 38.11M | 89.89M |
| Property, Plant & Equipment (Net) | 680K | 556K | 361K | 153K | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 9.17M | 5.59M | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 0 | 0 | 6K |
| Total Non-current Assets | 9.85M | 6.14M | 361K | 153K | 6K |
| Total Assets | 25.47M | 33.24M | 11.02M | 38.27M | 89.9M |
| Account Payables | 1.88M | 2.46M | 4.08M | 939K | 1.13M |
| Short-term Debt | 256K | 224K | 191K | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 35K | 17K | 17K | 0 | 0 |
| Other Current Liabilities | 3.2M | 788K | 4.7M | 1.51M | 2.17M |
| Total Current Liabilities | 8.5M | 7.71M | 10.62M | 5.2M | 6.64M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 18.67M | 18.67M | 18.67M | 18.67M |
| Other Non-current Liabilities | 1.26M | 684K | 110K | 100K | 152K |
| Total Non-current Liabilities | 1.75M | 19.69M | 18.95M | 18.77M | 18.82M |
| Total Liabilities | 10.25M | 27.4M | 29.57M | 23.97M | 25.46M |
| Common Stock | 901K | 27K | 27K | 32K | 39K |
| Retained Earnings | (248.83M) | (265.52M) | (281.04M) | (299.72M) | (326.69M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 24.96M | 16.58M | 6.13M | 2.1M | 0 |
| Total Equity | 15.22M | 5.84M | (18.55M) | 14.3M | 64.44M |
| Total Debt | 932K | 716K | 529K | 169K | 0 |
| Net Debt | (12.48M) | (11.41M) | (8.92M) | (36.58M) | (88.93M) |
vTv Therapeutics Inc.
NASDAQ:VTVT
Intrinsic Alpha fair value
Locked
Current Price
$16.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.